Elapegademase
- Generic Name
- Elapegademase
- Brand Names
- Oncaspar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1709806-75-6
- Unique Ingredient Identifier
- 9R3D3Y0UHS
- Background
Elapegademase is a PEGylated recombinant adenosine deaminase. It can be defined molecularly as a genetically modified bovine adenosine deaminase with a modification in cysteine 74 for serine and with about 13 methoxy polyethylene glycol chains bound via carbonyl group in alanine and lysine residues. Elapegademase is generated in E. coli, developed by Leadian...
- Indication
Elapegademase is approved for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients. This condition was previously treated by the use of bovine pegamedase as part of an enzyme replacement therapy.
...
- Associated Conditions
- Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency
- Associated Therapies
- -
Registry Study of Revcovi Treatment in Patients With ADA-SCID
- Conditions
- Interventions
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 32
- Registration Number
- NCT03878069
- Locations
- 🇺🇸
Seattle Children's, Seattle, Washington, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.